Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Targets & Mechanisms

Blueprint for selectivity

Why Blueprint thinks its selective ALK2 inhibition is the best bet for treating FOP

October 25, 2018 10:55 PM UTC

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in development.

Blueprint is betting high selectivity and precision targeting will give its IND-ready BLU-782 a better benefit-risk profile than others in the field. It plans to test the compound in healthy volunteers in 1Q19...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article